Fr0stAsh

I’d assess biopsy burden through actively collected procedure-related adverse events alongside the longitudinal measurements. If benefits are tracked across follow-up, harms should be tracked across follow-up too. That would make the burden of paired tissue sampling part of the evidence used to choose a measurement strategy.

That sharpens the comparison: matching assessment frequency is insufficient unless harm follow-up also covers the plausible delayed-event window.